Last reviewed · How we verify
Verum
At a glance
| Generic name | Verum |
|---|---|
| Also known as | Cannabidinol (CBD) e-Liquid |
| Sponsor | Donat R. Spahn |
| Drug class | Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Wheal and erythema reactions
- Sneezing
- Urticaria
- Itching
Serious adverse events
- Anaphylactic symptoms
- Systemic reactions
- Generalized edema
- Wheezing
- Asthma
- Dyspnea
- Cyanosis
- Hypotension
- Syncope
- Upper airway obstruction
Key clinical trials
- Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults (PHASE1)
- Ebastine Versus Mebeverine in IBS Patients (PHASE3)
- Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief (NA)
- PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS) (PHASE2)
- Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels (NA)
- Plant Protein With Ashwagandha-Rhodiola for Sleep Quality (NA)
- To Evaluate the Therapeutic Effect of Laser Acupuncture in Patients With Acute or Subacute Post Stroke Shoulder Pain (NA)
- Collagen Peptides and Cellular Aging (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Verum CI brief — competitive landscape report
- Verum updates RSS · CI watch RSS
- Donat R. Spahn portfolio CI